BIO Asia-Taiwan 2026, the region's flagship biotechnology event, was held at the Taipei Nangang Exhibition Center. To further expand its international biotech collaboration network and strengthen its product pipeline, the Taiwan Green Cross Business Development (BD) team attended the exhibition on 16–17 July, holding in-depth discussions with biopharmaceutical companies, drug developers and industry experts from around the world in pursuit of cross-border licensing and distribution opportunities.
Insights from the international supply chain forum
During the exhibition, the BD team attended the "International Forum on Pharmaceutical Supply Chain Resilience: From Manufacturing Self-Reliance to Global Market Access" held at Nangang Exhibition Hall 1 on 17 July. Focusing on manufacturing self-reliance and global market access strategies, the forum offered the team a deeper understanding of how global pharmaceutical supply chains are being reshaped, informing the company's future international market and regulatory strategy.
A two-way approach: in-licensing innovation, out-licensing Urokinase
With long-standing roots in Taiwan's healthcare market, Taiwan Green Cross offers complete commercialisation capabilities together with extensive hospital and clinic distribution networks. The company's participation centred on two strategic directions:
- In-licensing innovative products: Engaging with international biopharmaceutical companies looking to enter the Taiwanese market, as well as domestic developers approaching commercialisation, to evaluate finished products of clinical value — leveraging the company's distribution strengths to accelerate patient access to innovative medicines in Taiwan.
- Out-licensing for international markets: Promoting Urokinase, the company's long-established core thrombolytic product, to demonstrate Taiwan's development and manufacturing capabilities to potential overseas partners, and pursuing overseas distribution and technology out-licensing partnerships to raise the international profile of the company's own brand.
Remarks from General Manager Tsai-Ling Lin
Faced with the rapid transformation of the global pharmaceutical market and the reshaping of supply chains, Taiwan Green Cross has always upheld the philosophy of "introducing innovation, creating value and improving the quality of patient care". Through international events such as BIO Asia-Taiwan, we not only demonstrate the development capabilities and licensing potential of Taiwan's own Urokinase brand, but also hope to combine our deep clinical distribution strengths in Taiwan with global and local biotech partners — bringing in more breakthrough medical products and more complete treatment options for clinical teams and patients.
About Taiwan Green Cross
Taiwan Green Cross focuses on prescription pharmaceuticals, medical devices and healthcare. We are committed to introducing and developing innovative medical technologies and products, offering clinical professionals and patients more complete treatment and care options, while actively expanding into international markets to advance the globalisation of Taiwan's healthcare industry.